Bladder cancer is an important public health concern owing to its prevalence, high
recurrence risk and treatment failures. Maintaining the equilibrium between prompt and …

Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of
treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in …

Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …

Background Nivolumab has demonstrated antitumor activity and manageable safety in the
single-arm, phase II CheckMate 275 study in patients with unresectable locally advanced or …

The durability of response and general tolerability of checkpoint blockade has transformed
the treatment of metastatic urothelial carcinoma. However, only a minority of patients …

Overview Petros Grivas, MD, PhD is a board-certified Medical Oncologist at Seattle Cancer
Care Alliance, WA, USA. He also serves as Clinical Director of the University of Washington …

Close to the Bone: Tissue-Specific Checkpoint Immunotherapy Evasion Page 1 Leading
Edge Previews Close to the Bone: Tissue-Specific Checkpoint Immunotherapy Evasion …